Expanded access to bezuclastinib for systemic mastocytosis
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This program provides early access to bezuclastinib for people with systemic mastocytosis who are not getting enough help from current treatments and cannot join a clinical trial. It aims to offer a potential treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have systemic mastocytosis (any type, including non-advanced or advanced).
- You must be able to swallow tablets.
- Your current treatment is not controlling your disease well enough.
- You cannot be able to join or already be in another bezuclastinib clinical trial.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
This program provides access to bezuclastinib taken with sunitinib for people with advanced gastrointestinal stromal tumors (GIST) who cannot take imatinib or whose disease has worsened on imatinib. It aims to give treatment when no other clinical trial is available.
This study looks at a personalized approach to managing indolent systemic mastocytosis, a condition where too many mast cells build up in the body. The goal is to see if tailoring treatment based on individual characteristics can improve symptoms and quality of life.
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
This trial tests a combination of two drugs, avapritinib and decitabine, for people with systemic mastocytosis plus another blood cancer (SM-AHN). The goal is to see if the combination works better than either drug alone.
Hear when a new Systemic Mastocytoses, Indolent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.